Is Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)’s Fuel Running High? Reports Show Less Sellers

March 19, 2018 - By Michael Collier

 Is Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)’s Fuel Running High? Reports Show Less Sellers

Investors sentiment increased to 1.69 in Q3 2017. Its up 0.01, from 1.68 in 2017Q2. It is positive, as 12 investors sold BioCryst Pharmaceuticals, Inc. shares while 24 reduced holdings. 28 funds opened positions while 33 raised stakes. 79.80 million shares or 20.47% more from 66.24 million shares in 2017Q2 were reported.
Bnp Paribas Arbitrage accumulated 8,270 shares. 26,990 were reported by Sg Americas Securities Ltd Llc. Amer invested in 53,685 shares. Oakworth Capital Incorporated accumulated 100 shares or 0% of the stock. National Planning Corp has 32,000 shares for 0.03% of their portfolio. Rock Springs Capital Lp owns 0.11% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 450,000 shares. Proshare Advsrs Ltd has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 50,807 shares. Paloma Prtnrs has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Price T Rowe Associate Md holds 0% or 27,923 shares. Pura Vida Ltd Limited Liability Company holds 150,000 shares. Manufacturers Life Ins The invested in 62,981 shares or 0% of the stock. Voya Investment Ltd Liability Company stated it has 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). 6.98M are held by Ra Capital Mgmt Limited Com. Rhumbline Advisers invested in 95,458 shares. 500,000 were accumulated by Ghost Tree Cap Ltd Llc.

The stock of Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) registered a decrease of 10.43% in short interest. BCRX’s total short interest was 10.76 million shares in March as published by FINRA. Its down 10.43% from 12.02M shares, reported previously. With 1.67M shares average volume, it will take short sellers 6 days to cover their BCRX’s short positions. The short interest to Biocryst Pharmaceuticals Inc’s float is 15.11%.

The stock decreased 4.66% or $0.25 during the last trading session, reaching $5.12. About 363,696 shares traded. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 75.08% since March 19, 2017 and is uptrending. It has outperformed by 58.38% the S&P500.

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company has market cap of $504.86 million. The firm markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It currently has negative earnings. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Coverage

Among 14 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 12 have Buy rating, 0 Sell and 2 Hold. Therefore 86% are positive. BioCryst Pharmaceuticals has $16 highest and $2 lowest target. $7.20’s average target is 40.63% above currents $5.12 stock price. BioCryst Pharmaceuticals had 34 analyst reports since August 7, 2015 according to SRatingsIntel. Ladenburg Thalmann initiated BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) rating on Thursday, February 16. Ladenburg Thalmann has “Buy” rating and $11 target. The stock has “Buy” rating by J.P. Morgan on Wednesday, September 6. On Friday, August 7 the stock rating was upgraded by Zacks to “Sell”. Noble Financial maintained the stock with “Buy” rating in Friday, May 26 report. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Overweight” rating by Piperjaffray on Friday, August 12. The rating was downgraded by Bank of America on Wednesday, November 11 to “Underperform”. The firm has “Buy” rating given on Tuesday, August 8 by Noble Financial. As per Wednesday, January 6, the company rating was upgraded by Jefferies. The stock has “Buy” rating by H.C. Wainwright on Tuesday, January 23. On Wednesday, September 6 the stock rating was upgraded by Jefferies to “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.